Reduction in intracellular HCV RNA and virus protein expression in human hepatoma cells following treatment with 2′-O-methyl-modified anti-core deoxyribozyme

Virology

Volumn 377, Issue 2, 2008, Pages 339-344

  Trepanier, Janie B ^a,b   Tanner, Jerome E ^a   Alfieri, Caroline ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antiviral; Catalytic DNA; Deoxyribozyme; DNAzyme; HCV; HCV genomic RNA; Hepatitis C

Indexed keywords

2 O METHYL MODIFIED DEOXYRIBOZYME; CORE PROTEIN; DEOXYRIBOZYME; VIRUS PROTEIN; VIRUS RNA;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; FUNCTIONAL GENOMICS; GENE TARGETING; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SEQUENCE; RNA STRUCTURE; VIRUS REPLICATION; VIRUS STRAIN;

CARCINOMA, HEPATOCELLULAR; DNA, CATALYTIC; GENE EXPRESSION REGULATION, VIRAL; HEPACIVIRUS; HUMANS; RNA, VIRAL; VIRAL PROTEINS;

HEPATITIS C VIRUS;

EID: 45049085755     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.04.022     Document Type: Article

References (61)

1. Arase Y., Suzuki F., Tsubota A., Suzuki Y., Saitoh S., Kobayashi M., Akuta N., Someya T., Hosaka T., Kobayashi M., Sezaki H., Ikeda K., and Kumada H. Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load. Intervirology 47 (2004) 19-25
2. Beale G., Hollins A.J., Benboubetra M., Sohail M., Fox S.P., Benter I., and Akhtar S. Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system. J. Drug Target. 11 (2003) 449-456
3. Breaker R.R., Emilsson G.M., Lazarev D., Nakamura S., Puskarz I.J., Roth A., and Sudarsan N. A common speed limit for RNA-cleaving ribozymes and deoxyribozymes. RNA 9 (2003) 949-957
4. Brochot E., Duverlie G., Castelain S., Morel V., Wychowski C., Dubuisson J., and Francois C. Effect of ribavirin on the hepatitis C virus (JFH-1) and its correlation with interferon sensitivity. Antivir. Ther. 12 (2007) 805-813
5. Chakraborti S., and Banerjea A.C. Inhibition of HIV-1 gene expression by novel DNA enzymes targeted to cleave HIV-1 TAR RNA: potential effectiveness against all HIV-1 isolates. Molec. Ther. 7 (2003) 817-826
6. Chung R.T. Acute hepatitis C virus infection. Clin. Infect. Dis. 41 Suppl 1 (2005) S14-S17
7. Crooke S.T. Progress in antisense technology. Annu. Rev. Med. 55 (2004) 61-95
8. Dagle J.M., Walder J.A., and Weeks D.L. Targeted degradation of mRNA in Xenopus oocytes and embryos directed by modified oligonucleotides: studies of An2 and cyclin in embryogenesis. Nucleic Acids Res. 18 (1990) 4751-4757
9. Emilsson G.M., and Breaker R.R. Deoxyribozymes: new activities and new applications. Cell. Mol. Life Sci. 59 (2002) 596-607
10. Fahmy R.G., Waldman A., Zhang G., Mitchell A., Tedla N., Cai H., Geczy C.R., Chesterman C.N., Perry M., and Khachigian L.M. Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. Nat. Biotechnol. 24 (2006) 856-863
11. Gallo M., Montserrat J.M., and Iribarren A.M. Design and applications of modified oligonucleotides. Braz. J. Med. Biol. Res. 36 (2003) 143-151
12. Hoofnagle J.H. Hepatitis C: the clinical spectrum of disease. Hepatology 26 (1997) S15-S20
13. Hu Y., Cherton-Horvat G., Dragowska V., Baird S., Korneluk R.G., Durkin J.P., Mayer L.D., and LaCasse E.C. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin. Cancer Res. 9 (2003) 2826-2836
14. Hughes C.A., and Shafran S.D. Chronic hepatitis C virus management: 2000-2005 update. Ann. Pharmacother. 40 (2006) 74-82
15. Jason T.L., Koropatnick J., and Berg R.W. Toxicology of antisense therapeutics. Toxicol. Appl. Pharmacol. 201 (2004) 66-83
16. Judge A.D., Bola G., Lee A.C., and MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Molec. Ther. 13 (2006) 494-505
17. Kalota A., and Opalinska J.B. Design of antisense oligonucleotides and short interfering RNA duplexes (siRNA) targeted to BCL6 mRNA: towards rational drug development for specific lymphoma subsets. Blood Cells Mol. Diseases 38 (2007) 199-203
18. Kato T., Matsumura T., Heller T., Saito S., Sapp R.K., Murthy K., Wakita T., and Liang T.J. Production of infectious hepatitis C virus of various genotypes in cell cultures. J. Virol. 81 (2007) 4405-4411
19. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270 (2003) 1628-1644
20. Leone N., and Rizzetto M. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol. Dietol. 51 (2005) 31-46
21. Lima W.F., Brown-Driver V., Fox M., Hanecak R., and Bruice T.W. Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J. Biol. Chem. 272 (1997) 626-638
22. Lu Z.X., Ye M., Yan G.R., Li Q., Tang M., Lee L.M., Sun L.Q., and Cao Y. Effect of EBV LMP1 targeted DNAzymes on cell proliferation and apoptosis. Cancer Gene Ther. 12 (2005) 647-654
23. Mangia A. Short-duration therapy for hepatitis C: suitable for all?. J. Viral Hepatitis 14 (2007) 221-227
24. Moradpour D., and Blum H.E. A primer on the molecular virology of hepatitis C. Liver Int. 24 (2004) 519-525
25. Moriishi K., and Matsuura Y. Evaluation systems for anti-HCV drugs. Adv. Drug Deliv. Rev. 59 (2007) 1213-1221
26. Oketani M., Asahina Y., Wu C.H., and Wu G.Y. Inhibition of hepatitis C virus-directed gene expression by a DNA ribonuclease. J. Hepatol. 31 (1999) 628-634
27. Pietschmann T., Kaul A., Koutsoudakis G., Shavinskaya A., Kallis S., Steinmann E., Abid K., Negro F., Dreux M., Cosset F.L., and Bartenschlager R. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7408-7413
28. Randall G., Grakoui A., and Rice C.M. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 235-240
29. Randall G., Panis M., Cooper J.D., Tellinghuisen T.L., Sukhodolets K.E., Pfeffer S., Landthaler M., Landgraf P., Kan S., Lindenbach B.D., Chien M., Weir D.B., Russo J.J., Ju J., Brownstein M.J., Sheridan R., Sander C., Zavolan M., Tuschl T., and Rice C.M. Cellular cofactors affecting hepatitis C virus infection and replication. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 12884-12889
30. Romero-Lopez C., Sanchez-Luque F.J., and Berzal-Herranz A. Targets and tools: recent advances in the development of anti-HCV nucleic acids. Infect. Dis. Drug Targets 6 (2006) 121-145
31. Rouille Y., Helle F., Delgrange D., Roingeard P., Voisset C., Blanchard E., Belouzard S., McKeating J., Patel A.H., Maertens G., Wakita T., Wychowski C., and Dubuisson J. Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J. Virol. 80 (2006) 2832-2841
32. Sambrook J., Fritsch E.F., and Maniatis T. Mapping of RNA with ribonuclease and radiolabeled RNA probes. In: Nolan C. (Ed). Molecular Cloning: A Laboratory Manual (1989), Cold Spring Harbor Press, Cold Spring Harbor 7.71-7.78
33. Santoro S.W., and Joyce G.F. A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 4262-4266
34. Santoro S.W., and Joyce G.F. Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry 37 (1998) 13330-13342
35. Schubert S., Furste J.P., Werk D., Grunert H.P., Zeichhardt H., Erdmann V.A., and Kurreck J. Gaining target access for deoxyribozymes. J. Mol. Biol. 339 (2004) 355-363
36. Schubert S., Gul D.C., Grunert H.P., Zeichhardt H., Erdmann V.A., and Kurreck J. RNA cleaving '10-23' DNAzymes with enhanced stability and activity. Nucleic Acids Res. 31 (2003) 5982-5992
37. Seo M.Y., Abrignani S., Houghton M., and Han J.H. Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. J. Virol. 77 (2003) 810-812
38. Sheldon J., Barreiro P., and Vincent V. Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection. Expert Opin. Investig. Drugs 16 (2007) 1171-1181
39. Shiffman M.L., Suter F., Bacon B.R., Nelson D., Harley H., Sola R., Shafran S.D., Barange K., Lin A., Soman A., and Zeuzem S. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 357 (2007) 124-134
40. Smith R.M., and Wu G.Y. Structure-based design of hepatitis C virus inhibitors. J. Viral Hepatitis 10 (2003) 405-412
41. Smith R.M., Walton C.M., Wu C.H., and Wu G.Y. Secondary structure and hybridization accessibility of hepatitis C virus 3′-terminal sequences. J. Virol. 76 (2002) 9563-9574
42. Smith R.M., Smolic R., Volarevic M., and Wu G.Y. Positional effects and strand preference of RNA interference against hepatitis C virus target sequences. J. Viral Hepatitis 14 (2007) 194-212
43. Sood V., Unwalla H., Gupta N., Chakraborti S., and Banerjea A.C. Potent knock down of HIV-1 replication by targeting HIV-1 Tat/Rev RNA sequences synergistically with catalytic RNA and DNA. AIDS 21 (2007) 31-40
44. Sookoian S.C. New therapies on the horizon for hepatitis C. Ann. Hepatol. 2 (2003) 164-170
45. Swiatkowska A., Dutkiewicz M., and Ciesiolka J. Structural features of target RNA molecules greatly modulate the cleavage efficiency of trans-acting delta ribosymes. Biochemistry 46 (2007) 5523-5533
46. Takahashi H., Hamazaki H., Habu Y., Hayashi M., Abe T., Miyano-Kurosaki N., and Takaku H. A new modified DNA enzyme that targets influenza virus A mRNA inhibits viral infection in cultured cells. FEBS Lett. 560 (2004) 69-74
47. Takamizawa A., Mori C., Fuke I., Manabe S., Murakami S., Fujita J., Onishi E., Andoh T., Yoshida I., and Okayama H. Structure and organization of the hepatitis C virus genome isolated from human carriers. J. Virol. 65 (1991) 1105-1113
48. Thurner C., Witwer C., Hofacker I.L., and Stadler P.F. Conserved RNA secondary structures in Flaviviridae genomes. J. Gen. Virol. 85 (2004) 1113-1124
49. Timm J., and Roggendorf M. Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J. Gastroenterol. 13 (2007) 4808-4817
50. Trepanier J.B., Tanner J.E., and Alfieri C. Oligonucleotide-based therapeutic options against hepatitis C virus infection. Antivir. Ther. 11 (2006) 273-287
51. Trepanier J., Tanner J.E., Momparler R.L., Le O.N., Alvarez F., and Alfieri C. Cleavage of intracellular hepatitis C RNA in the virus core protein coding region by deoxyribozymes. J. Viral Hepatitis 13 (2006) 131-138
52. Tuplin A., Evans D.J., and Simmonds P. Detailed mapping of RNA secondary structures in core and NS5B-encoding region sequences of hepatitis C virus by RNase cleavage and novel bioinformatic prediction methods. J. Gen. Virol. 85 (2004) 3037-3047
53. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., and Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11 (2005) 791-796
54. Watanabe T., Umehara T., Yasui F., Nakagawa S.I., Yano J., Ohgi T., Sonoke S., Satoh K., Inoue K., Yoshiba M., and Kohara M. Liver target delivery of small interfering RNA to the HCV gene by lactosylated cationic liposome. J. Hepatol. 47 (2007) 744-750
55. Westerhout E.M., Ooms M., Vink M., Das A.T., and Berkhout B. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res. 33 (2005) 796-804
56. Wilson J.A., and Richardson C.D. Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region. J. Virol. 79 (2005) 7050-7058
57. Yasui K., Wakita T., Tsukiyama-Kohara K., Funahashi S.I., Ichikawa M., Kajita T., Moradpour D., Wands J.R., and Kohara M. The native form and maturation process of hepatitis C virus core protein. J. Virol. 72 (1998) 6048-6055
58. Yen L., Strittmatter S.M., and Kalb R.G. Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA. Ann. Neurol. 46 (1999) 366-373
59. Zein N.N. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. 13 (2000) 223-235
60. Zhao C.A., Zhao X.D., Yu H.G., Wu Y.P., and Yang X.Q. Inhibition of respiratory syncytial virus replication in cultured cells by RNA-cleaving DNAzyme. Zhonghua Er. Ke. Za Zhi. 41 (2003) 594-597
61. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31 (2003) 3406-3415